Profile data is unavailable for this security.
About the company
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
- Revenue in USD (TTM)0.00
- Net income in USD-33.01m
- Incorporated2013
- Employees14.00
- LocationBioVie Inc680 W NYE LANE, SUITE 201CARSON CITY 89703United StatesUSA
- Phone+1 (775) 888-3162
- Websitehttps://www.bioviepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioCardia Inc | 428.00k | -8.56m | 9.28m | 16.00 | -- | -- | -- | 21.68 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
Galecto Inc | 0.00 | -25.43m | 9.35m | 13.00 | -- | 0.3445 | -- | -- | -23.45 | -23.45 | 0.00 | 21.74 | 0.00 | -- | -- | 0.00 | -59.06 | -48.46 | -75.34 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
Molecular Templates Inc | 25.47m | -15.63m | 9.36m | 62.00 | -- | 1.32 | -- | 0.3674 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
GlycoMimetics Inc | 10.00k | -39.11m | 9.85m | 35.00 | -- | 0.4911 | -- | 985.31 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
Curative Biotechnology Inc | 0.00 | -6.02m | 9.94m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
Kiora Pharmaceuticals Inc | 16.02m | 2.67m | 10.22m | 12.00 | -- | 0.3087 | 3.79 | 0.6379 | -7.76 | -7.76 | 6.61 | 11.14 | 0.5279 | -- | 7.16 | 1,335,000.00 | 10.54 | -70.52 | 11.20 | -81.86 | -- | -- | 19.98 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
Conduit Pharmaceuticals Inc | 0.00 | -5.17m | 10.22m | 7.00 | -- | -- | -- | -- | -0.0667 | -0.0667 | 0.00 | -0.0738 | 0.00 | -- | -- | 0.00 | -312.39 | -- | -- | -- | -- | -- | -- | -- | -- | -21.32 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
BioVie Inc | 0.00 | -33.01m | 10.30m | 14.00 | -- | 0.515 | -- | -- | -7.92 | -7.92 | 0.00 | 2.51 | 0.00 | -- | -- | 0.00 | -106.51 | -330.64 | -176.17 | -875.72 | -- | -- | -- | -- | -- | -- | 0.2688 | -- | -- | -- | 34.32 | -- | -- | -- |
Kintara Therapeutics Inc | 0.00 | -9.51m | 10.52m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
IN8BIO, Inc. | 0.00 | -31.96m | 10.54m | 31.00 | -- | 0.7677 | -- | -- | -0.8357 | -0.8357 | 0.00 | 0.2933 | 0.00 | -- | -- | 0.00 | -122.41 | -74.18 | -146.35 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0945 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Oncotelic Therapeutics Inc | 70.00k | -1.24m | 10.56m | 22.00 | -- | 0.8711 | -- | 150.90 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
Turnstone Biologics Corp | 0.00 | -74.70m | 10.66m | 82.00 | -- | 0.1785 | -- | -- | -3.49 | -3.49 | 0.00 | 2.58 | 0.00 | -- | -- | 0.00 | -98.52 | -- | -127.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
Senti Biosciences Inc | 338.00k | -78.62m | 10.90m | 48.00 | -- | 0.2465 | -- | 32.24 | -17.52 | -12.65 | 0.0749 | 9.66 | 0.0029 | -- | 1.12 | 7,041.67 | -68.20 | -- | -74.50 | -- | -- | -- | -23,259.47 | -- | -- | -- | 0.0023 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
Tron Pharmaceuticals Inc | 1.01m | -549.47k | 11.04m | 50.00 | -- | -- | -- | 10.94 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
Tenax Therapeutics Inc | 0.00 | -12.57m | 11.18m | 5.00 | -- | 0.7236 | -- | -- | -22.35 | -22.35 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -101.95 | -199.16 | -113.79 | -285.64 | -- | -- | -- | -- | -- | -95.94 | 0.0305 | -- | -- | -- | 30.21 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Altium Capital Management LPas of 31 Mar 2024 | 3.01m | 4.93% |
Sabby Management LLCas of 31 Mar 2024 | 689.14k | 1.13% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 619.11k | 1.01% |
Heights Capital Management, Inc.as of 31 Mar 2024 | 599.90k | 0.98% |
swisspartners AGas of 30 Jun 2023 | 300.00k | 0.49% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 286.71k | 0.47% |
Geode Capital Management LLCas of 30 Jun 2024 | 231.66k | 0.38% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 175.17k | 0.29% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 103.35k | 0.17% |
Cerity Partners LLCas of 31 Mar 2024 | 82.74k | 0.14% |